Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-105826-6e561b44",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "mini-max",
  "action": "propose",
  "content": "\n\n# Novel Hypotheses: Pathological vs. Adaptive Metabolic Changes in Neurodegeneration\n\n## Hypothesis 1: Temporal Phase-Shift Model of Glycolytic Adaptation\n\n**Description:** Glycolytic shifts in early neurodegeneration represent adaptive responses that preserve ATP under impaired oxidative phosphorylation, but become pathological when they trigger sustained epigenetic remodeling and locked-in transcriptional programs. The transition point—the \"point of no return\"—is characterized by irreversible histone acetylation changes at metabolic genes.\n\n**Target:** HDAC2/3 activity; SIRT3 deacetylase function\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 2: Cell-Type Metabolic Dichotomy\n\n**Description:** Identical glycolytic shifts carry opposite functional meanings across cell types: in post-mitotic neurons, metabolic inflexibility reflects pathological loss of adaptability due to limited regenerative capacity; in glia, the same shifts represent beneficial stress responses enabling survival. Single-nucleus transcriptomics of early vs. late disease stages can distinguish these trajectories by mapping metabolic gene signatures per cell type.\n\n**Target:** Neuronal vs. astrocytic PKM2 isoform switching (PKM2 vs. PKM1)\n\n**Confidence:** 0.68\n\n---\n\n## Hypothesis 3: Metabolic Reserve Capacity as Pathological Discriminator\n\n**Description:** True pathological metabolic changes exhibit diminished reserve—the capacity to increase flux through alternative pathways under challenge—while adaptive changes preserve or enhance reserve. Acute stress testing (glucose challenge, hypoxia) combined with Seahorse respirometry can differentiate: low reserve = primary pathology; maintained reserve = secondary adaptation.\n\n**Target:** Mitochondrial coupling efficiency; spare respiratory capacity\n\n**Confidence:** 0.75\n\n---\n\n## Hypothesis 4: mTOR Biphasic Disruption Model\n\n**Description:** mTOR inhibition in early neurodegeneration is a beneficial adaptive response—reducing protein synthesis burden, activating autophagy, mimicking fasting—that becomes pathological when chronic due to loss of synaptic protein homeostasis. The therapeutic window depends on disease stage: acute mTOR inhibition is protective; sustained inhibition reproduces pathology.\n\n**Target:** mTORC1 (Raptor); Rheb GTPase activity\n\n**Confidence:** 0.79\n\n---\n\n## Hypothesis 5: NAD⁺ Regeneration Coupling Hypothesis\n\n**Description:** Glycolytic shifts are adaptive when coupled to functional NAD⁺ regeneration via salvage pathways (Preiss-Handler pathway, NAD⁺ kinases); they become pathological when NAD⁺ depletion occurs, disrupting sirtuins, PARPs, and CD38. Imaging NAD⁺/NADH ratios in vivo via specialized probes can determine coupling status and predict therapeutic windows.\n\n**Target:** NMNAT1/2/3; NAMPT; NAD⁺ kinases\n\n**Confidence:** 0.71\n\n---\n\n## Hypothesis 6: Epigenetic Lock-In Checkpoint Hypothesis\n\n**Description:** Pathological metabolic changes are characterized by CpG methylation and histone modifications that stabilize the glycolytic phenotype (e.g., methylation of PGC-1α promoter), preventing return to oxidative metabolism. Adaptive changes lack these epigenetic signatures. This checkpoint represents the irreversible transition from adaptive to pathological.\n\n**Target:** DNMT1 activity; DNMT3a/b; MBD proteins\n\n**Confidence:** 0.64\n\n---\n\n## Hypothesis 7: Secondary Metabolic Inflexibility Fingerprinting\n\n**Description:** If metabolic inflexibility is secondary to upstream stressors (proteostasis failure, calcium dysregulation), then measuring primary insult markers (ubiquitin aggregates, calpain activation) should precede and predict metabolic dysfunction. Treatment of the primary stress should normalize metabolism in adaptive cases but fail in primary metabolic disease.\n\n**Target:** Calpain activation fragments; ubiquitinated protein aggregates\n\n**Confidence:** 0.70\n\n---\n\n## Summary Table\n\n| Hypothesis | Primary Distinction | Confidence |\n|------------|---------------------|------------|\n| 1 | Temporal irreversibility | 0.72 |\n| 2 | Cell-type specificity | 0.68 |\n| 3 | Reserve capacity testing | 0.75 |\n| 4 | mTOR biphasic effects | 0.79 |\n| 5 | NAD⁺ coupling status | 0.71 |\n| 6 | Epigenetic lock-in | 0.64 |\n| 7 | Primary vs. secondary etiology | 0.70 |\n\nThese hypotheses offer testable frameworks for resolving the pathological/adaptive distinction, with direct implications for therapeutic targeting strategies.",
  "tokens_used": "1105"
}